Pneumococcal disease (PD), caused by , is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to systematically review the cost-effectiveness of current PCVs (pneumococcal conjugate vaccines) and PPVs (pneumococcal polysaccharide vaccine) from 2018 to April 2024. Articles were identified through PubMed, Embase, and Cochrane. Key outcomes include an improved incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY), with the article's quality assessed via the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022). In total, 23 studies were included, with 22 studies of high quality and 1 of moderate quality. These articles showed that PCV20 was the most cost-effective option compared with other vaccines, including PPV23, PCV13, PCV15, and PCV15/PPV23, for both young and older adults, regardless of risk factors. PCV20, when used alone, saved greater costs than PCV20, followed by PPV23. For countries applying lower-valency vaccines, switching to PCV20 as a single regimen would be the most beneficial for averting pneumococcal cases and reducing costs in adults aged 18-64 and over 65.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11641157 | PMC |
| http://dx.doi.org/10.3390/healthcare12232490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.
PLoS One
January 2025
Bangladesh Council of Scientific and Industrial Research (BCSIR), Dhaka, Bangladesh.
Streptococcus pneumoniae (SPN) is a significant pathogen causing pneumonia and meningitis, particularly in vulnerable populations like children and the elderly. Available pneumonia vaccines have limitations since they only cover particular serotypes and have high production costs. The emergence of antibiotic-resistant SPN strains further underscores the need for a new, cost-effective, broad-spectrum vaccine.
View Article and Find Full Text PDFEvaluation of Integrated Child Health Days as a Catch-Up Strategy for Immunization in Three Districts in Uganda.
Vaccines (Basel)
November 2024
U.S. Centers for Disease Control and Prevention, Global Immunization Division, Global Health Center, Atlanta, GA 30329, USA.
Uganda's Integrated Child Health Day (ICHD) initiative aims to improve children's access to vaccinations. Although widely used as a catch-up vaccination strategy, the effectiveness of the ICHD program in increasing immunization coverage, especially among vulnerable populations, has not been recently evaluated. This study assessed the reach and uptake of ICHD for immunizations in Uganda.
View Article and Find Full Text PDFHealth state utilities associated with invasive pneumococcal disease, pneumonia, and recurrent acute otitis media in young children.
Qual Life Res
January 2025
MRL, Merck & Co., Inc., Rahway, NJ, USA.
Purpose: Cost-utility analyses examining the value of new vaccines for pneumococcal disease will require health state utilities as inputs. Existing utilities for pneumococcal infections in young children are limited. The purpose of this study was to estimate health state utilities associated with pneumococcal infections in young children.
View Article and Find Full Text PDFSystematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.
Vaccine
December 2024
Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA. Electronic address:
Article Synopsis
- The review examined cost-effectiveness analyses of new adult pneumococcal vaccines (PCV15 and PCV20) across different countries.
- Most studies found that PCV20 offered cost savings or was more cost-effective than older vaccination strategies in high-income countries.
- Assumptions about vaccine effectiveness, duration of protection, and herd immunity effects varied, with most studies considered low-risk for bias.
Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach.
J Med Econ
December 2025
Merck & Co., Inc, Rahway, NJ, USA.
Introduction: This study analyzed the health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) and the 20-valent pneumococcal conjugate vaccine (PCV20), as well as their relative cost-effectiveness, in Japanese adults aged 65 years using a delta pricing approach.
Methods: A Markov model was employed to simulate the movement of the Japanese population among four health states: healthy, pneumococcal disease (consisting of invasive pneumococcal disease [IPD] with or without meningitis and non-bacteremic pneumococcal pneumonia [NBPP]), post-meningitis sequelae, and death. The model was populated with publicly available demographic and epidemiologic data, stratified by risk level.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!